{"filing":{"accession_number":"0001104659-26-096478","cik":"0001649989","ticker":"OTLK","company_name":"Outlook Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-14","primary_document":"tm2622399d3_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926096478/tm2622399d3_8k.htm"},"events":[{"id":27746,"run_id":25320,"accession_number":"0001104659-26-096478","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The filing discloses Outlook Therapeutics' third quarter fiscal year 2026 financial results (ended June 30, 2026), including net loss of $20.3 million ($0.15 per share) and adjusted net loss of $10.9 million ($0.09 per share). The press release in Exhibit 99.1 is a standard earnings announcement that reports quarterly financial results alongside a business update on the FDA approval of LYTENAVA and commercial launch preparations. This is a material earnings disclosure under Item 2.02.","company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29411,"accession_number":"0001104659-26-096478","item_number":"2.02","item_title":"and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Outlook Therapeutics' third quarter fiscal year 2026 financial results (ended June 30, 2026), including net loss of $20.3 million ($0.15 per share) and adjusted net loss of $10.9 million ($0.09 per share). The press release in Exhibit 99.1 is a standard earnings announcement that reports quarterly financial results alongside a business update on the FDA approval of LYTENAVA and commercial launch preparations. This is a material earnings disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T12:04:06.772220+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29411,"accession_number":"0001104659-26-096478","item_number":"2.02","item_title":"and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Outlook Therapeutics' third quarter fiscal year 2026 financial results (ended June 30, 2026), including net loss of $20.3 million ($0.15 per share) and adjusted net loss of $10.9 million ($0.09 per share). The press release in Exhibit 99.1 is a standard earnings announcement that reports quarterly financial results alongside a business update on the FDA approval of LYTENAVA and commercial launch preparations. This is a material earnings disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T12:04:06.772220+00:00","company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","filing_date":"2026-08-14"}]}